Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intramuscular ergotamine: plasma levels and dynamic activity.

P Tfelt-Hansen, L Paalzow

    Clinical Pharmacology and Therapeutics
    |January 1, 1985
    PubMed
    Summary

    Ergotamine tartrate effectively treats migraine by affecting peripheral arteries, but its therapeutic use requires anticipating patient variability in drug response and sensitivity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Interictal "patchy" regional cerebral blood flow patterns in migraine patients. A single photon emission computerized tomographic study.

    European journal of neurology·2013
    Same author

    CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine.

    Cephalalgia : an international journal of headache·2010
    Same author

    Posterior hypoperfusion in migraine without aura?

    Cephalalgia : an international journal of headache·2010
    Same author

    Nitroglycerin provocation in normal subjects is not a useful human migraine model?

    Cephalalgia : an international journal of headache·2009
    Same author

    Guidelines for controlled trials of drugs in tension-type headache: second edition.

    Cephalalgia : an international journal of headache·2009
    Same author

    Prednisolone reduces nitric oxide-induced migraine.

    European journal of neurology·2009

    Area of Science:

    • Pharmacology
    • Clinical Pharmacology
    • Vascular Medicine

    Background:

    • Migraine is a debilitating neurological disorder often treated with ergotamine tartrate.
    • Understanding the pharmacokinetics and pharmacodynamics of ergotamine tartrate is crucial for optimizing migraine therapy.

    Purpose of the Study:

    • To investigate the pharmacokinetic and pharmacodynamic profile of intramuscular ergotamine tartrate in migraine patients.
    • To model the drug's absorption, distribution, and effect on peripheral arteries.

    Main Methods:

    • Intramuscular injection of ergotamine tartrate (0.5 mg) in 10 migraine subjects.
    • Measurement of peripheral arterial effects (toe-arm systolic gradients).
    • Plasma concentration analysis using High-Performance Liquid Chromatography (HPLC) and pharmacokinetic modeling.

    Main Results:

    • Ergotamine tartrate demonstrated a slow onset and sustained effect on peripheral arteries (lasting over 29 hours).
    • Rapid absorption (t1/2 = 3 min) and a biologic half-life of 2.5 hours were observed.
    • A pharmacokinetic-pharmacodynamic (PK/PD) model indicated a slow equilibration between plasma and effector sites (t1/2 = 9.9 hours).
    • Significant inter-subject variability was found in the concentration for 50% of maximal effect (Cpss50), with a coefficient of variation of 110%.

    Conclusions:

    • Ergotamine tartrate's vascular effects are sustained, despite rapid absorption and decline in plasma levels.
    • Therapeutic use of ergotamine tartrate necessitates consideration of both pharmacokinetic and dynamic variability among patients.
    • Individual differences in drug sensitivity significantly impact treatment outcomes for migraine patients using ergotamine tartrate.

    Related Experiment Videos